Please login to the form below

Bioverativ

This page shows the latest Bioverativ news and features for those working in and with pharma, biotech and healthcare.

Dupixent drives Sanofi again, but other new drugs are lagging

There was bad news for Genzyme’s blood disorders unit, however. Long-acting haemophilia A drug Eloctate – acquired as part of Sanofi’s $11.9bn acquisition of Bioverativ last year – succumbed

Latest news

EMA clears Novo Nordisk’s long-acting haemophilia A drug

Takeda’s Shire unit already has a long-acting factor VIII product on the market in Adynovate, as does Sanofi with Eloctate from its recent Bioverativ acquisition, Bayer with Kovaltry, and
Hudson named Brandicourt’s successor as Sanofi’s CEO

He also bolstered the company’s pipeline with acquisitions of Ablynx and Bioverativ for 3.9bn and $11.6bn, respectively, building a franchise in rare blood diseases, but missed out to
Bicycle Therapeutics looks to raise $86m with IPO

The company has research collaborations with AstraZeneca in respiratory, cardiovascular and metabolic disease, Bioverativ in non-malignant haematology indications, including haemophilia and with Oxurion in ophthalmology.
Sobi shows strong growth despite haemophilia competition

countries. Marketing rights to the drugs in the US, Canada and Japan are held by Bioverativ, which was acquired last year by Sanofi.
Sanofi exits R&D pact with Alnylam on rare disease

Bioverativ an Ablynx last year. ... Haemophilia and other rare blood diseases have become key therapeutic targets for Sanofi in the wake of its acquisition of Bioverativ – which gave it long-acting clotting factor therapies Eloctate and

More from news
Approximately 3 fully matching, plus 21 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Biogen's spin-out, Bioverativ, had not even got past its first anniversary as a Nasdaq-listed company before being snapped up by Sanofi for $11.6bn (although this is not ... only with its rare disease focus but also enhances its portfolio of products for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Industry appointments

Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... The firm has managed to poach Bioverativ’s senior executive Rogerio Vivaldi (pictured
Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

the chief executive officer and president of Syntonix Pharmaceuticals - a wholly owned subsidiary of Biogen, now Bioverativ - and vice president of global operations.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Experienced / Senior Medical Writer - Excellent Progression Oppo...: Excellent Salary and Benefits on offer

Senior Copywriter: Salary TBC

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior / Principal Medical Writers wanted - MedComms - Various U...: Excellent Remuneration Packages

Senior Medical Writer – Medical Communications – North West – In...: Excellent Remuneration Package

Account Director, Medical Education: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Editorial Assistants - Medical Communications agency - Cheshire: Excellent Remuneration Package

Senior Medical Writer: Salary TBC

Senior Account Manager / Account Director - MedComms - London: Highly competitive salary &package

Subscribe to our email news alerts

PMHub

Add my company

Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe: By Richard Springham...
The Golden Goose: Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?: Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...